New Zealand markets closed
  • NZX 50

    11,372.62
    +53.88 (+0.48%)
     
  • NZD/USD

    0.5963
    +0.0031 (+0.52%)
     
  • NZD/EUR

    0.5596
    +0.0037 (+0.67%)
     
  • ALL ORDS

    7,270.00
    +3.40 (+0.05%)
     
  • ASX 200

    7,068.80
    +3.60 (+0.05%)
     
  • OIL

    90.33
    +0.70 (+0.78%)
     
  • GOLD

    1,944.90
    +5.30 (+0.27%)
     
  • NASDAQ

    14,701.10
    +6.85 (+0.05%)
     
  • FTSE

    7,683.91
    +5.29 (+0.07%)
     
  • Dow Jones

    33,963.84
    -106.58 (-0.31%)
     
  • DAX

    15,557.29
    -14.57 (-0.09%)
     
  • Hang Seng

    18,057.45
    +402.04 (+2.28%)
     
  • NIKKEI 225

    32,402.41
    -168.62 (-0.52%)
     
  • NZD/JPY

    88.4560
    +0.9600 (+1.10%)
     

3 Things About Moderna That Smart Investors Know

Prior to the pandemic, Moderna (NASDAQ: MRNA) was like many other small biotechs. In fact, for the full year of 2019, Moderna had only $60 million in revenue, entirely from collaborations and grants, and it posted a net loss of $514 million. As we know, Moderna's ability to rapidly produce a vaccine for the COVID-19 virus changed the financial prospects for the company and put it in a completely different position today.